Mesoblast drew down US$50 million from a five-year facility provided by existing shareholder and director Dr. Gregory George. The company had US$122 million cash as of March 30, 2026, and plans to use the funds to invest in commercial operations and its growth pipeline, as well as to retire the higher-cost NovaQuest Capital Management LLC debt facility, eliminating short-term debt obligations. The credit line carries a fixed interest rate of 8.00% per annum with a five-year interest-only period, secured solely by the Temcell royalty, and can be repaid at any time without early prepayment or exit fees. Chief Executive Silviu Itescu stated that the facility strengthens the balance sheet and does not encumber material assets or intellectual property, allowing unrestricted entry into strategic partnerships or licensing transactions.
Mesoblast LtdMesoblast is retiring the NovaQuest debt facility, reducing NovaQuest's interest income and relationship.